Abstract
PKC-θ is a serine/threonine specific protein kinase and its activation depends upon the concentration of diacylglycerol (DAG) and phospholipids (phosphatidylserine). PKC-θ phosphorylates a variety of proteins that are known to be involved in the diverse cellular signaling pathways. It is predominantly expressed in the T-cells and localized in the center of immunological synapse upon T-cell receptor (TCR) and CD28 signaling. Activation of PKC-θ leads to the activation of various transcription factors in the nuclei of T-cells, e.g. NF-κB, NFAT, c-Jun, c-Fos and AP-1 that further control the proliferation and differentiation of T-cells. Defective T-cell activation in turn leads to the aberrant expression of apoptosis related proteins that cause the poor T-cell survival. Researchers have found that T-cells deficient in PKC-θ exhibit reduced interleukin-2 (IL-2) production. Apart from this role on IL-2 expression, it also plays crucial roles in the proliferation, differentiation and survival of the T-cells, which make it an attractive therapeutic target for a variety of immunological and T-cell mediated diseases. Hence, new molecules capable of modulating the expression or biological activity of PKC-θ are being developed and tested for their potential as novel therapy for several T-cells mediated disease conditions such as multiple sclerosis, rheumatoid arthritis, asthma, inflammatory bowel disease and organ transplantation, etc. In the present review, we tried to integrate the recent discoveries on PKC-θ including its pharmacology and therapeutic potential, along with brief update on its inhibitor molecules.
Keywords: Autoimmune diseases, diacylglycerol (DAG), NF-κB, protein kinase C theta (PKC-θ), rheumatoid arthritis (RA), phospholipids, T-cells, CD28 signaling, interleukin-2, inflammatory bowel disease.
Current Pharmaceutical Design
Title:Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders
Volume: 18 Issue: 30
Author(s): Sukhvir Chand, Nisha Mehta, Malkeet Singh Bahia, Anshuman Dixit and Om Silakari
Affiliation:
Keywords: Autoimmune diseases, diacylglycerol (DAG), NF-κB, protein kinase C theta (PKC-θ), rheumatoid arthritis (RA), phospholipids, T-cells, CD28 signaling, interleukin-2, inflammatory bowel disease.
Abstract: PKC-θ is a serine/threonine specific protein kinase and its activation depends upon the concentration of diacylglycerol (DAG) and phospholipids (phosphatidylserine). PKC-θ phosphorylates a variety of proteins that are known to be involved in the diverse cellular signaling pathways. It is predominantly expressed in the T-cells and localized in the center of immunological synapse upon T-cell receptor (TCR) and CD28 signaling. Activation of PKC-θ leads to the activation of various transcription factors in the nuclei of T-cells, e.g. NF-κB, NFAT, c-Jun, c-Fos and AP-1 that further control the proliferation and differentiation of T-cells. Defective T-cell activation in turn leads to the aberrant expression of apoptosis related proteins that cause the poor T-cell survival. Researchers have found that T-cells deficient in PKC-θ exhibit reduced interleukin-2 (IL-2) production. Apart from this role on IL-2 expression, it also plays crucial roles in the proliferation, differentiation and survival of the T-cells, which make it an attractive therapeutic target for a variety of immunological and T-cell mediated diseases. Hence, new molecules capable of modulating the expression or biological activity of PKC-θ are being developed and tested for their potential as novel therapy for several T-cells mediated disease conditions such as multiple sclerosis, rheumatoid arthritis, asthma, inflammatory bowel disease and organ transplantation, etc. In the present review, we tried to integrate the recent discoveries on PKC-θ including its pharmacology and therapeutic potential, along with brief update on its inhibitor molecules.
Export Options
About this article
Cite this article as:
Chand Sukhvir, Mehta Nisha, Singh Bahia Malkeet, Dixit Anshuman and Silakari Om, Protein Kinase C-theta Inhibitors: A Novel Therapy for Inflammatory Disorders, Current Pharmaceutical Design 2012; 18 (30) . https://dx.doi.org/10.2174/138161212802651625
DOI https://dx.doi.org/10.2174/138161212802651625 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Emerging Diabetes Online Community
Current Diabetes Reviews Patent Selections
Recent Patents on Biomarkers Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Multifaceted Synthesis, Properties and Applications of Polyurethanes and its Composites
Current Organic Chemistry Inhaled Biologics: From Preclinical to Product Approval
Current Pharmaceutical Design Paeonol, a Powerful Natural Product with Broad Biological Spectra by Inhibiting Inflammatory Pathway
Current Traditional Medicine The Regulation of FoxP3-Expressing Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Phytochemistry and Phytotherapeutic Aspects of <i>Elaeagnus angustifolia L.</i>
Current Drug Discovery Technologies Oxidative Stress and Cancer: The Role of Nrf2
Current Cancer Drug Targets Measuring T Cell Cytokines in Allergic Upper and Lower Airway Inflammation: Can We Move to the Clinic?
Inflammation & Allergy - Drug Targets (Discontinued) Oxidative and Nitrosative Stress in the Pathogenesis of Obstructive Lung Diseases of Increasing Severity
Current Medicinal Chemistry A Network Pharmacology Approach to Reveal the Underlying Mechanisms of Zuogui Yin in the Treatment of Male Infertility
Combinatorial Chemistry & High Throughput Screening Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies
Current Medicinal Chemistry Past Efforts and Future Prospects for a Nasal Influenza Vaccine
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Nanoparticles, Neurotoxicity and Neurodegenerative Diseases
Current Drug Metabolism Electroconvulsive Therapy in Child and Adolescent Psychiatry
Current Psychiatry Reviews Influence of Toll-Like-Receptor Ligands on the Dendritic Cell - T Cell Interactions: Therapeutic Options for Allergic Diseases? Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) A Review of Epidemiological Evidence on Short-Term Effects of Environmental Factors on Respiratory Problems in Children
Current Respiratory Medicine Reviews NF-κB in Anti-Inflammatory Activity of Probiotics: An Update
Current Immunology Reviews (Discontinued) Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Topics in Medicinal Chemistry